Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Tianda Pharmaceuticals's quarterly market cap
declined
from Dec. 2024 (HK$363.4 Mil) to Jun. 2025 (HK$290.3 Mil) and
declined
from Jun. 2025 (HK$290.3 Mil) to Dec. 2025 (HK$277.4 Mil).
Tianda Pharmaceuticals's annual market cap
declined
from Dec. 2023 (HK$468.7 Mil) to Dec. 2024 (HK$363.4 Mil) and
declined
from Dec. 2024 (HK$363.4 Mil) to Dec. 2025 (HK$277.4 Mil).
Enterprise Value is the theoretical takeover price. It is more comprehensive than market capitalization (market cap), which only includes common equity. Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash and cash equivalents. Tianda Pharmaceuticals's Enterprise Value for Today is HK$338.6 Mil.
Tianda Pharmaceuticals (HKSE:00455) Market Cap Explanation
Market cap is not the real price you pay for a company. If you buy the company and become its owner, you become the owner of the cash the company has, and you also assume the companys debt. The real price you pay is the Enterprise Value.
Warren Buffett uses the ratio of total market cap of all public traded companies over GDP to measure if the market is expensive. As of April 2012, the US total market cap is about $14.7 trillion, while the US GDP is about $15 trillion. The market was modestly overvalued.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Tianda Pharmaceuticals's Market Cap, along with its competitors' market caps and Market Cap data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Tianda Pharmaceuticals Market Cap vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Tianda Pharmaceuticals's Market Cap distribution charts can be found below:
* The bar in red indicates where Tianda Pharmaceuticals's Market Cap falls into.
Market cap is the short version of market capitalization. It is the total market value to buy the whole company. It is equal to the share price times the number of shares outstanding.
Tianda Pharmaceuticals's Market Cap for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Tianda Pharmaceuticals (HKSE:00455) has a Market Cap of HK$238.7 Mil as of Aug. 23, 2026. Market cap equals the total value of a company's shares: price times shares outstanding. View historical data on Tianda Pharmaceuticals and its competitors. According to the industry distribution chart, Tianda Pharmaceuticals ranks #764 out of 1021 companies in the Drug Manufacturers industry, placing it in the top 74.8%.
Is Tianda Pharmaceuticals' Market Cap too high?
Tianda Pharmaceuticals' current Market Cap is HK$238.7 Mil. Based on the distribution chart, Tianda Pharmaceuticals ranks #764 out of 1021 companies in the Drug Manufacturers industry, which is below the industry midpoint. Overall, Tianda Pharmaceuticals has a GF Score™ of 24/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Tianda Pharmaceuticals' Market Cap compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Tianda Pharmaceuticals ranks #764 out of 1021 companies for Market Cap. This places Tianda Pharmaceuticals in the lower half of its industry. The industry median Market Cap is 234.76. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Market Cap for a Drug Manufacturers company?
The median Market Cap among Drug Manufacturers companies is 234.76, based on 1,021 companies in the industry. Companies in the top quartile (top 25%) have a Market Cap significantly above this median, while those in the bottom quartile fall well below. However, Market Cap should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Market Cap mean?
A high Market Cap can signal that a stock is expensive relative to its fundamentals. Market cap equals the total value of a company's shares: price times shares outstanding. View historical data on Tianda Pharmaceuticals and its competitors. For the Drug Manufacturers industry, the median Market Cap is 234.76 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Tianda Pharmaceuticals's current Market Cap is HK$238.7 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Tianda Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, Tianda Pharmaceuticals (HKSE:00455) is currently considered Modestly Undervalued. The stock's GF Value™ is HK$0.13, compared to a current price of HK$0.11 — trading 14.6% below its estimated fair value. The current Market Cap is HK$238.7 Mil. Tianda Pharmaceuticals' overall GF Score™ is 24/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Market Cap calculated?
Market Cap is calculated from a company's financial statements. For Tianda Pharmaceuticals (HKSE:00455), the current Market Cap is HK$238.7 Mil as of Aug. 23, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Tianda Pharmaceuticals (HKSE:00455) Overvalued in 2026?
Based on GuruFocus' analysis, Tianda Pharmaceuticals stock appears to be undervalued.
The current stock price of HK$0.11 is trading 14.6% below its estimated GF Value™ of HK$0.13.
GuruFocus considers Tianda Pharmaceuticals to be Modestly Undervalued.
Key valuation signals for HKSE:00455:
Market Cap: HK$238.7 Mil
GF Value™: HK$0.13 vs. price of HK$0.11 (14.6% below fair value)
No single metric tells the full story. See the HKSE:00455 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Tianda Pharmaceuticals Ltd is engaged in research and development, manufacturing, and sales of pharmaceutical, biotechnology, and healthcare products, and investment in the development of the Chinese medicine industry. The group also engages in research and development of Chinese medicine, sales of Chinese herbal medicines, traditional Chinese medicine decoction pieces and Chinese medicine, and provision of Chinese medicine clinical services. Its operating segments include the Chinese medicine business; Medical and healthcare services; and Pharmaceuticals and medical technologies business. The company derives the majority of its revenue from the Pharmaceuticals and medical technologies business. Its geographical segments include Mainland China, Hong Kong, and Australia.
24GF Score
Get the complete analysis for HKSE:00455
Market Cap is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
HKSE:00455 has been successfully added to your 
